VivoSim Labs, Inc.

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company specializing in the testing of drugs and drug candidates using advanced three-dimensional (3D) human tissue models of the liver and intestine. The company employs proprietary new approach methodologies (NAM) to provide detailed insights into liver and intestinal toxicology, aiding pharmaceutical and biotech partners in investigational toxicology, mechanism of drug action elucidation, and prediction of side effect profiles during drug development. VivoSim Labs builds functional 3D human tissues that closely mimic native tissue composition, architecture, and function, including disease states, utilizing high-throughput systems, bioprinting, and flow/stretch-capable technologies. Formerly known as Organovo Holdings, Inc., the company was renamed in April 2025 and has its headquarters in San Diego, California. VivoSim Labs plays a significant role in advancing drug safety and efficacy testing through sophisticated tissue engineering and predictive toxicology platforms, contributing to improved preclinical evaluation in the healthcare biotechnology sector.